On Monday, Shares of Banco Bradesco SA (ADR) (NYSE:BBD), gained 4.78% to $5.92, as Brazil’s real gains on a lower likelihood that the Federal Reserve will improvement interest rates during 2015.
The real strengthened 0.5% to 3.9141 per dollar at 9:36 a.m. in Sao Paulo, as poor U.S. employment data for September weighs on the Fed’s ability to hike interest rates this year and consequently improvements demand for riskier assets, Bloomberg reports.
However, the currency is down 32% this year, with Brazil facing an economic recession worsened by political turmoil as lawmakers attempt to oust President Dilma Rousseff, according to Bloomberg.
Banco Bradesco S.A. (the Bank) is a commercial bank. The Bank offers a range of banking and financial products and services in Brazil and abroad to individuals, companies and local and international corporations and institutions.
Shares of Charles Schwab Corp (NYSE:SCHW), inclined 2.77% to $28.36, during its last trading session.
The Charles Schwab Corporation, declared recently it is adding five new ETFs to Schwab ETF OneSource™, the program that offers investors and advisors the most commission-free* ETFs anywhere in the industry. All five of the new additions are currency-hedged ETFs, and come at a time when monetary policy and currency fluctuations around the world are garnering substantial attention and assets in the category are growing at a rapid pace.
Schwab ETF OneSource offers commission-free ETFs from 14 leading providers – ALPS, Direxion, ETF Securities, Global X Funds, Guggenheim Investments, IndexIQ, J.P. Morgan Asset Administration, PIMCO, PowerShares, ProShares, State Street SPDR® ETFs, United States Commodity Funds, WisdomTree and Charles Schwab Investment Administration.
The Charles Schwab Corporation (CSC) is a savings and loan holding company. Through its auxiliaries, the Company engages in wealth administration, securities brokerage, banking, money administration and financial advisory services. The Company provides financial services to individuals and institutional clients through two segments: Investor Services and Advisor Services.
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), declined -2.81% to $58.37, during its last trading session.
Teva Pharmaceutical Industries, declared recently that Lancet Neurology published online, as back-to-back articles, the results from two Phase 2b studies of TEV-48125, a monoclonal anti-calcitonin gene-related peptide (CGRP) antibody investigational treatment for the prevention of chronic migraine and high frequency episodic migraine (HFEM). The Lancet Neurology ranks first among 194 journals in the clinical neurology category (2013 Journal Citation Reports®, Thomson Reuters 2014).
The Phase 2b clinical development program consistently met all primary and secondary efficacy and safety endpoints for TEV-48125 in 564 patients and across multiple doses. Clinical improvements were exhibited after a single administration of all tested doses of TEV-48125 in both episodic and chronic migraine studies.
These results were achieved in the presence of patients being allowed to remain on existing migraine prevention therapy and the results demonstrated noteworthy separation in favor of TEV-48125 even in patients considered to be failing current optimal therapy.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company’s generic products cover almost every major therapeutic area.
Finally, Actuant Corporation (NYSE:ATU), ended its last trade with 10.05% gain, and closed at $20.80.
Actuant Corporation, declared results for its fourth quarter and fiscal year ended August 31, 2015.
Fourth Quarter Highlights
- Fourth quarter total sales declined 15% year-over-year with 8% attributable to the strengthening of the US dollar. Core sales were down 7% (total sales not taking into account the impact of acquisitions, divestitures and foreign currency rate changes).
- Diluted earnings per share (“EPS”) were $0.37 in the fourth quarter of fiscal 2015 as compared to $0.47 in the prior year, which excluded a $0.04 divestiture gain (see “Merged Results” below and attached reconciliation of earnings).
- Continued tight cost control with the year-over-year percentage reduction in selling, administrative and engineering (SA&E) expense surpassing that of the sales decline for the second successive quarter.
- Strong fourth quarter free cash flow resulting in full year free cash flow conversion of over 100% of net earnings for the 15th successive year.
- Introduced fiscal 2016 full year sales and EPS guidance of $1.16-1.20 billion and $1.20-1.40, respectively, not taking into account restructuring charges associated with incremental cost reduction actions.
Actuant Corporation is a global diversified company that designs, manufactures and distributes a range of industrial products and systems to various end markets. The Company is organized into three operating segments: Industrial, Energy and Engineered Solutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
